258 related articles for article (PubMed ID: 26954716)
21. The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes.
Althobiti M; Muftah AA; Aleskandarany MA; Joseph C; Toss MS; Green A; Rakha E
Breast Cancer Res Treat; 2020 Aug; 182(3):581-589. PubMed ID: 32524353
[TBL] [Abstract][Full Text] [Related]
22. AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer.
Liu D
Cell Oncol (Dordr); 2020 Apr; 43(2):321-333. PubMed ID: 31933152
[TBL] [Abstract][Full Text] [Related]
23. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
24. Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer.
Aljohani AI; Joseph C; Kurozumi S; Mohammed OJ; Miligy IM; Green AR; Rakha EA
Breast Cancer Res Treat; 2020 Jun; 181(3):541-551. PubMed ID: 32350677
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens.
Carroll JS; Swarbrick A; Musgrove EA; Sutherland RL
Cancer Res; 2002 Jun; 62(11):3126-31. PubMed ID: 12036924
[TBL] [Abstract][Full Text] [Related]
26. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
[TBL] [Abstract][Full Text] [Related]
27. Prognostic and predictive significance of MYC and KRAS alterations in breast cancer from women treated with neoadjuvant chemotherapy.
Pereira CB; Leal MF; de Souza CR; Montenegro RC; Rey JA; Carvalho AA; Assumpção PP; Khayat AS; Pinto GR; Demachki S; de Arruda Cardoso Smith M; Burbano RR
PLoS One; 2013; 8(3):e60576. PubMed ID: 23555992
[TBL] [Abstract][Full Text] [Related]
28. ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC.
Griffin NI; Sharma G; Zhao X; Mirza S; Srivastava S; Dave BJ; Aleskandarany M; Rakha E; Mohibi S; Band H; Band V
Breast Cancer Res; 2016 Nov; 18(1):113. PubMed ID: 27852327
[TBL] [Abstract][Full Text] [Related]
29. MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.
Venturutti L; Cordo Russo RI; Rivas MA; Mercogliano MF; Izzo F; Oakley RH; Pereyra MG; De Martino M; Proietti CJ; Yankilevich P; Roa JC; Guzmán P; Cortese E; Allemand DH; Huang TH; Charreau EH; Cidlowski JA; Schillaci R; Elizalde PV
Oncogene; 2016 Dec; 35(48):6189-6202. PubMed ID: 27157613
[TBL] [Abstract][Full Text] [Related]
30. Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib.
Kim JY; Park K; Im SA; Jung KH; Sohn J; Lee KS; Kim JH; Yang Y; Park YH
Breast Cancer Res Treat; 2020 Dec; 184(3):743-753. PubMed ID: 32860168
[TBL] [Abstract][Full Text] [Related]
31. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer.
Jacquemier J; Charafe-Jauffret E; Monville F; Esterni B; Extra JM; Houvenaeghel G; Xerri L; Bertucci F; Birnbaum D
Breast Cancer Res; 2009; 11(2):R23. PubMed ID: 19405945
[TBL] [Abstract][Full Text] [Related]
32. The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer.
El Ansari R; Alfarsi L; Craze ML; Masisi BK; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2020 May; 181(1):1-12. PubMed ID: 32200487
[TBL] [Abstract][Full Text] [Related]
33. c-Myc overexpression and endocrine resistance in breast cancer.
McNeil CM; Sergio CM; Anderson LR; Inman CK; Eggleton SA; Murphy NC; Millar EK; Crea P; Kench JG; Alles MC; Gardiner-Garden M; Ormandy CJ; Butt AJ; Henshall SM; Musgrove EA; Sutherland RL
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):147-55. PubMed ID: 17052904
[TBL] [Abstract][Full Text] [Related]
34. Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory role of the MAPK and PI3K pathways in estrogen receptor-negative breast cancers.
Manzano RG; Martinez-Navarro EM; Forteza J; Brugarolas A
Int J Oncol; 2014 Dec; 45(6):2250-66. PubMed ID: 25201346
[TBL] [Abstract][Full Text] [Related]
35. MYC Targets Scores Are Associated with Cancer Aggressiveness and Poor Survival in ER-Positive Primary and Metastatic Breast Cancer.
Schulze A; Oshi M; Endo I; Takabe K
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33143224
[No Abstract] [Full Text] [Related]
36. Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity.
Van Keymeulen A; Lee MY; Ousset M; Brohée S; Rorive S; Giraddi RR; Wuidart A; Bouvencourt G; Dubois C; Salmon I; Sotiriou C; Phillips WA; Blanpain C
Nature; 2015 Sep; 525(7567):119-23. PubMed ID: 26266985
[TBL] [Abstract][Full Text] [Related]
37. PI3K/AKT Signaling in Breast Cancer Molecular Subtyping and Lymph Node Involvement.
Bonin S; Pracella D; Barbazza R; Dotti I; Boffo S; Stanta G
Dis Markers; 2019; 2019():7832376. PubMed ID: 31781306
[TBL] [Abstract][Full Text] [Related]
38. Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup.
Alles MC; Gardiner-Garden M; Nott DJ; Wang Y; Foekens JA; Sutherland RL; Musgrove EA; Ormandy CJ
PLoS One; 2009; 4(3):e4710. PubMed ID: 19270750
[TBL] [Abstract][Full Text] [Related]
39. Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.
Joseph C; Macnamara O; Craze M; Russell R; Provenzano E; Nolan CC; Diez-Rodriguez M; Sonbul SN; Aleskandarany MA; Green AR; Rakha EA; Ellis IO; Mukherjee A
Br J Cancer; 2018 Apr; 118(8):1142-1151. PubMed ID: 29588513
[TBL] [Abstract][Full Text] [Related]
40. MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.
Gogas H; Kotoula V; Alexopoulou Z; Christodoulou C; Kostopoulos I; Bobos M; Raptou G; Charalambous E; Tsolaki E; Xanthakis I; Pentheroudakis G; Koutras A; Bafaloukos D; Papakostas P; Aravantinos G; Psyrri A; Petraki K; Kalogeras KT; Pectasides D; Fountzilas G
J Transl Med; 2016 May; 14(1):136. PubMed ID: 27184134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
